REVISED PROGRAMME BUDGET 2020-2021 HUMAN REPRODUCTION PROGRAMME (HRP)
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
REVISED PROGRAMME BUDGET 2020–2021 HUMAN REPRODUCTION PROGRAMME (HRP) Department of Sexual and Reproductive Health and Research including UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)
REVISED PROGRAMME BUDGET 2020–2021 HUMAN REPRODUCTION PROGRAMME (HRP) Department of Sexual and Reproductive Health and Research including UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)
Human Reproduction Programme (HRP) revised programme budget 2020-2021 ISBN 978-92-4-000776-5 (electronic version) ISBN 978-92-4-000777-2 (print version) © World Health Organization 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (http://www.wipo.int/amc/en/mediation/rules/) Suggested citation. HRP revised programme budget 2020-2021. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps. who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.
CONTENTS ACRONYMS AND ABBREVIATIONS IV 1. INTRODUCTION 1 1.1 HRP’s mandate in sexual and reproductive health and rights 1 1.2 Impact of HRP’s work 3 1.3 HRP’s theory of change 4 1.4 HRP programme budget and operational plan, 2020–2021 4 1.5 Monitoring and accountability 10 2. HRP THEMATIC AREAS 11 A. Family planning and contraception 11 B. Maternal and perinatal health 14 C. Safe abortion 19 D. STIs, HIV linkages and cervical cancer 21 F. Fertility care 24 G. Sexual health 26 H. Violence against women and girls 28 I. Adolescent sexual and reproductive health and rights 30 J. Female genital mutilation 33 K. Sexual and reproductive health and rights in health emergencies 35 M. Human rights, gender equality and social determinants 38 N. Health systems, including self-care and digital innovations 40 O. Measuring and monitoring indicators 44 P. HRP Alliance 46 Q. General technical and programme management activities 48 3. MATERNAL MORTALITY PROJECT 53 4. HRP BUDGET TABLES 55 REFERENCES 58 HRP REVISED PROGRAMME BUDGET, 2020-2021 iii
LIST OF TABLES
Table 1. H
RP programme budget and indicative budget for WHO/HQ
core work in SRHR (US$ thousands) 8
Table 2. H
RP budget summary for 2020–2021, by thematic area (products only) 55
Table 3. H
RP budget summary for 2020–2021, by budget section 55
Table 4. H
RP budget summary for 2020–2021, by budget section (products only) 56
Table 5. H
RP budget for 2020–2021 compared with 2018-2019,
by thematic area (products only) 56
Table 6. S
RH Department consolidated income requirements and sources
of funds for 2020–2021 57
LIST OF FIGURES
Figure 1. WHO’s 13th General Programme of Work 2
Figure 2. HRP programme budget 2020–2021, by thematic area (product budget only) 6
Figure 3. SRH Department and HRP’s contribution to the
WHO General Programme of Work 6
Figure 4. HRP budget 2018–2019 and 2020–2021, by thematic area (product budget only) 9
ACRONYMS AND ABBREVIATIONS
AMR antimicrobial resistance
ART assisted reproductive technologies
CCS Country Cooperation Strategy
DMPA depot medroxyprogesterone acetate (injectable contraceptive method)
ECHO Evidence for Contraceptive Options and HIV Outcomes Study
EMTCT elimination of mother-to-child transmission
EPMM Ending Preventable Maternal Mortality
FGM female genital mutilation
FHW front-line health worker
GAMA Global Action for Measurement of Adolescent health
GAP HRP Gender and Rights Advisory Panel
Global Strategy Global Strategy for Women’s, Children’s and Adolescents’ Health 2016-2030
GPW13 WHO’s 13th General Programme of Work
GRC WHO Guidelines Review Committee
HPV human papillomavirus
HRP UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research,
Development and Research Training in Human Reproduction; also “Human
Reproduction Programme”
HSV herpes simplex virus
IAP Independent Advisory Panel
ICD International Classification of Diseases
iv HRP REVISED PROGRAMME BUDGET, 2020-2021
ICD-11 International Classification of Diseases 11th revision IPU Inter-Parliamentary Union IUD intrauterine device LGBTI lesbian, gay, bisexual, transgender and intersex MAR medically assisted reproduction mHealth mobile health MPTs multipurpose prevention technologies POCTS point-of-care tests PCC HRP Policy and Coordination Committee PHC primary health care QED Quality, equity, dignity RCS research capacity strengthening RCT randomized controlled trial RTIS reproductive tract infections SDG Sustainable Development Goal SRH WHO Department of Sexual and Reproductive Health and Research SRHR sexual and reproductive health and rights STAG HRP Scientific and Technical Advisory Group STI sexually transmitted infection UHC universal health coverage UN United Nations UNDP United Nations Development Programme UNFPA United Nations Population Fund UNICEF United Nations Children’s Fund WHE WHO Health Emergencies Programme WHO World Health Organization HRP REVISED PROGRAMME BUDGET, 2020-2021 v
iv HRP REVISED PROGRAMME BUDGET, 2020-2021
INTRODUCTION
1.1 RP’S MANDATE IN SEXUAL AND
H
REPRODUCTIVE HEALTH AND RIGHTS
Established in 1972, the UNDP-UNFPA- at the World Health Assembly in 2004. This
UNICEF-WHO-World Bank Special Programme forward-looking strategy remains central to
of Research, Development and Research WHO and HRP’s work in sexual and reproductive
Training in Human Reproduction (also referred health and rights to the present day.
to as the Human Reproduction Programme
or HRP) is the main instrument within the In September 2015, the Sustainable Development
United Nations (UN) system for research in Goals (SDGs) of the 2030 Agenda for Sustainable
human reproduction, bringing together policy- Development2 were formally adopted by world
makers, scientists, health-care providers, leaders at an historic UN Summit, and these
clinicians and community representatives to officially came into force on 1 January 2016.
identify and address priorities for research Several targets were established for SRHR
to improve sexual and reproductive health. issues, primarily within Goals 3 (Ensure healthy
lives and promote well-being for all at all ages)
HRP is a cosponsored Special Programme and 5 (Achieve gender equality and empower
executed by the World Health Organization all women and girls); these targets provide
(WHO), embedded within WHO’s Department countries, as well as WHO and HRP, with clear
of Sexual and Reproductive Health and directions and targets for the coming decade.
Research (SRH) to ensure strong linkages
between the evidence-based outputs of HRP In 2019, WHO launched an ambitious, but
and the normative guidance and programme achievable, five-year strategic plan: WHO’s
development roles of WHO. Indicative budget 13th General Programme of Work (GPW13),
levels for WHO core normative and programme covering the period from 2019 to 2023. GPW13,
development for sexual and reproductive health which is explicitly linked to the SDGs, focuses
and rights are shown on Table 6 on page 57. on a new “triple billion” target to provide a billion
more people with universal health coverage,
The overall mandate for the work of HRP in to protect one more billion people from health
sexual and reproductive health and rights (SRHR) emergencies and to provide a further billion
is guided by the global Reproductive health people with better health and well-being. This
strategy,1 adopted by WHO Member States “triple billion” target is shown in Figure 1.
HRP REVISED PROGRAMME BUDGET, 2020-2021 1
FIGURE 1. WHO’S 13TH GENERAL PROGRAMME OF WORK
IE R POPULA
TH TI
AL
O
1 billion more
NS
HE
people enjoying
better health
and well-being
1 billion 1 billion
VERAGE
more people more people
protected benefitting
from health from universal
emergencies health coverage
HE A
CO
H
LT
TH
EM UN L
E RGENCIES IV EA
ERSAL H
The GPW13 reflects WHO’s ambitions to become a stronger, more efficient and results-
oriented organization that will serve and guide governments and partners as part of a collective
effort to improve the health of their populations and to achieve Sustainable Development
Goal 3. The “triple billion” goal is a joint effort of Member States, WHO, HRP, and other
partners. No single actor operating alone can achieve these goals. Contributions are required
from many partners – principally Member States themselves, but also non-State actors and
the WHO and HRP Secretariat. Consequently, there is a need for both collective action and
accountability, as well as for demonstrating the contribution made to outcomes and impact.
These three coordinated international agreements, taken together, form a bold new roadmap for SRHR
as they aim to keep women, children and adolescents at the heart of the sustainable development
agenda, unlocking their vast potential for transformative change and impact at the country level.
These agreements also provide a strong global mandate for rigorous research that can produce the
empirical evidence needed by countries to achieve the high goals of both GPW13 and the SDGs.
2 HRP REVISED PROGRAMME BUDGET, 2020-20211.2 IMPACT OF HRP’S WORK
In 2015, UN Member States adopted the 2030 Agenda for Sustainable Development and its
17 Sustainable Development Goals (SDGs). This is a universal set of goals, targets and indicators
that Member States will use to frame their agendas and political policies over the next 15
years. Since its inception, HRP has led ground-breaking work underpinning many of the SDG
targets. Through this programme of work, HRP aims to impact the SDG targets shown in the box.
BOX 1. HRP’s SDG TARGETS
3.1. By 2030, reduce the global maternal mortality ratio
to less than 70 per 100 000 live births
3.7. By 2030, ensure universal access to sexual and reproductive
health-care services, including for family planning, information
and education, and the integration of reproductive
health into national strategies and programmes
5.1. End all forms of discrimination against all women and girls everywhere
5.2. Eliminate all forms of violence against all women and girls
in the public and private spheres, including trafficking
and sexual and other types of exploitation
5.3. Eliminate all harmful practices, such as child, early and
forced marriage and female genital mutilation
5.6. Ensure universal access to sexual and reproductive health
and reproductive rights as agreed in accordance with the
Programme of Action of the International Conference on
Population and Development and the Beijing Platform for Action
and the outcome documents of their review conferences
9.5. Enhance scientific research, upgrade the technological
capabilities of industrial sectors in all countries, in particular
low- and middle-income countries, including, by 2030,
encouraging innovation and substantially increasing the number
of research and development workers per 1 million people and
public and private research and development spending
HRP REVISED PROGRAMME BUDGET, 2020-2021 31.3 HRP’S THEORY OF CHANGE
HRP’s work is guided by a theory of change, PCC Members, HRP cosponsors, advisory
which is expressed through a results framework. bodies, and WHO staff. This theory of change
This was developed in 2018-2020 following is described in detail in a separate document
an extensive consultative process involving which was approved by PCC in March 2020.
1.4 RP PROGRAMME BUDGET AND OPERATIONAL
H
PLAN, 2020–2021
The HRP programme budget 2020–2021 Agenda for Sustainable Development and reach
is based on a list of technical products, the “triple billion” targets. This revised budget
milestones for achievement during the was therefore presented for PCC approval in
biennium, and planned contributions to the March 2020. Whilst the WHO transformation
outputs shown on the following pages. As in resulted in some proposed changes in the
the past, each product has been assigned detailed product tables throughout the current
a priority level,* which will determine the document, the thematic area budget levels
order of funding and implementation over are unchanged from the levels approved
the course of the biennium. Following the by PCC in March 2019. The breakdown of
practice established in 2018-2019, the work proposed is shown by thematic area
products in 2020–2021 are organized in Figure 2. The data are also presented by
according to thematic areas established in budget section in the budget tables in Part 4
the HRP Portfolio Review conducted in 2016, of this document, to enable clear linkages with
which are shown in the box on the right. organizational and managerial structure.
A draft budget for 2020–2021 was presented The workplan and budget of HRP is fully
to STAG in February 2019 for its advice and integrated within and contributes to WHO’s
guidance. Following STAG, it was revised GPW13, which covers the period from 2019
and submitted as a proposal for PCC and to 2023, as well as the WHO’s programme
was approved in March 2019. In approving budget 2020–20213 which was presented
this budget at its March 2019 meeting, to the World Health Assembly in May 2019.
PCC requested the Secretariat to submit a Specifically, all the outcomes anticipated in the
revised budget in March 2020, if needed to HRP budget contribute to one or more of the
accommodate the ongoing transformation “Triple Billion” targets in the GPW and WHO
process at WHO to strengthen the Programme Budget, as shown in Figure 3.
Organization’s capacity to deliver the 2030
* If the programme budget is fully funded, all products will be implemented, but the order of implementation will
be based on receipt of funds. At the beginning of the biennium, ongoing research projects and other activities
to which HRP has already made a commitment to implement will be funded (“Priority A”) and implementation will
begin. As receipt of additional funding permits, new critical products and deliverables will be added (“Priority B”).
4 HRP REVISED PROGRAMME BUDGET, 2020-2021BOX 2. HRP THEMATIC AREAS, 2020–2021 A. Family planning and contraception B. Maternal and perinatal health C. Safe abortion D. Sexually transmitted infections, HIV linkages, and cervical cancer F. Fertility care G. Sexual health H. Violence against women and girls I. Adolescent SRHR J. Female genital mutilation K. SRHR in health emergencies M. Human rights, gender equality and social determinants N. Health systems, including self-care and digital innovations O. Measuring and monitoring indicators P. HRP Alliance HRP REVISED PROGRAMME BUDGET, 2020-2021 5
FIGURE 2. HRP PROGRAMME BUDGET 2020–2021, BY THEMATIC AREA (PRODUCT BUDGET ONLY)**
1.6% Human rights, gender equality and social determinants
SRHR in health emergencies
Health systems, including self
care and digital innovations
Female genital mutilation 1.8%
Adolescent SRHR 6.1% Measuring and monitoring indicators
6.1%
Violence against 4.8% 4.4%
women and girls
HRP Alliance
Sexual health 1.7% 3.7%
8.3%
Fertility care 2.4%
General technical
STIs, HIV linkages 4.7%
and cervical cancer 7.3% HRP PROGRAMME
BUDGET 2020-2021
8.3%
Programme management
12.2%
Safe abortion 9.7%
Family planning and contraception
16.9%
Maternal and perinatal health
** For budget details please refer to Table 2 on page 55.
FIGURE 3. SRH DEPARTMENT AND HRP’S CONTRIBUTION TO THE WHO GENERAL PROGRAMME OF WORK
WHO “TRIPLE BILLION” TARGETS Achieving universal Addressing health Promoting healthier Focusing global public
health coverage emergencies – 1 billion populations – 1 billion goods on impact –
– 1 billion more more people better more people enjoying normative guidance
people benefitting protected from health better health and and agreements; data,
from universal emergencies well-being research and innovation
health coverage
PRIMARY GPW13 OUTPUTS 1.1.3. 2.3.3. 3.1.1. 4.1.3.
FOR SRH AND HRP Countries enabled Essential health Countries enabled Countries enabled to
to strengthen their services delivered and to address social strengthen research
health systems to systems maintained determinants of health capacity and systems,
address population- and strengthened across the life course conduct and use
specific health needs in humanitarian and research on public
and barriers to equity vulnerable settings health priorities,
across the life course and scale effective
innovations in a
sustainable manner
6 HRP REVISED PROGRAMME BUDGET, 2020-2021IMPACT OF SRH DEPARTMENT AND HRP WORK ON WHO
“TRIPLE BILLION” TARGETS, BY THEMATIC AREA
A. F
amily planning and
contraception ••• •• •• ••
B. Maternal and perinatal health
•• • • •••
C. Safe abortion ••• •• •• •••
D. STIs, HIV, and cervical cancer •• • •• •••
F. Fertility care
• •• ••
G. Sexual health
• •• ••
H. Violence against
women and girls ••• •• •• ••
I. Adolescent SRHR
•• •• •• ••
J. Female genital mutilation
•• •• ••
K. SRHR in health emergencies • ••• •• ••
M. H
uman rights, gender equality
and social determinants • •• ••• ••
N. Health systems, self-care,
digital innovations •• • •• •••
O. M
easuring and
monitoring indicators •• •• •• •••
P. HRP Alliance ••• • • •••
Maternal mortality project ••• • •
The operational plans for HRP and the The budget levels for HRP are shown in Table 1,
WHO SRH Department are shown together alongside indicative budget levels for WHO/
throughout this document, although funding HQ core work in SRHR which are included for
remains separate. The source of funding completeness. The changes in product (activity)
for each product is indicated in the product level budgets are shown in Figure 4. More
and milestone tables presented for each detailed data are shown in the budget tables
thematic area in Part 2 of this document. in Part 4 of this report, beginning on page 55.
HRP REVISED PROGRAMME BUDGET, 2020-2021 7TABLE 1. H
RP PROGRAMME BUDGET AND INDICATIVE BUDGET FOR WHO/
HQ CORE WORK IN SRHR (US$ THOUSANDS)
2018–2019 2020–2021
PERCENT CHANGE
Budget US$ Percent Budget US$ Percent
UNDP-UNFPA-UNICEF-WHO-World Bank Special
Programme of Research, Development and
Research Training in Human Reproduction (HRP)
Products 41 040 60.0% 41 040 60.0% 0.0%
Staff positions 27 360 40.0% 27 360 40.0% 0.0%
Subtotal HRP Core 68 400 100% 68 400 100.0% 0.0%
Global Maternal Mortality Project 25 000 50 000 +50.0%
Total HRP 93 400 118 400 +21.1%
WHO core budget (SRH Department)
Products 8 105 50.3% 8 105 50.3% 0.0%
Staff positions 8 000 49.7% 8 000 49.7% 0.0%
Total WHO Core 16 105 100.0% 16 105 100.0% 0.0%
Grand total SRH Department 109 505 134 505 +18.6%
8 HRP REVISED PROGRAMME BUDGET, 2020-2021FIGURE 4. RP BUDGET 2018–2019 AND 2020–2021, BY THEMATIC AREA (PRODUCT BUDGET ONLY)***
H
2018 – 19 US$ Millions
2020 – 21
0 1 2 3 4 5 6 7 8
Maternal and perinatal health
Safe abortion
Family planning and contraception
HPR Alliance
Programme management
STIs, HIV linkages and cervical cancer
Health systems, including self care
& digital innovations
SRHR in health emergencies
Adolescent SRHR
General technical activities
Measuring and monitoring indicators
Violence against women and girls
Fertility care
Female genital mutilation
Sexual health
Human rights, gender equality
& social determinants
*** For budget details please refer to Table 5 on page 56.
HRP REVISED PROGRAMME BUDGET, 2020-2021 91.5 MONITORING AND ACCOUNTABILITY
The success of HRP’s work in sexual and • The Research Project Review Panel
reproductive health and rights depends on (RP2) provides an independent
its scientific and ethical rigour, its leadership scientific and ethical review and
and commitment to human rights and approval for every research proposal
gender equality, and its capacity to address funded by HRP; it also meets annually
global priorities that are also important for to assess the review process.
countries, particularly low- and middle-income
countries. This implies continual monitoring • The work of the HRP Alliance is monitored
of the programme outcomes and output and evaluated at annual meetings of the
indicators. Monitoring is carried out by several HRP Alliance Steering Committee. At
complementary advisory and governing bodies. these meetings, progress is reviewed and
evaluated, and plans for the coming year
• The HRP Theory of Change includes a are developed. HRP research capacity
detailed results framework, that includes strengthening projects are reviewed by
output, outcome, and impact indicators the HRP Alliance Steering Committee.
and qualitative evaluation approaches
that that are reported to PCC. • HRP is evaluated at the annual meetings
of the Policy and Coordination
• The HRP Scientific and Technical Committee (PCC), at biannual meetings
Advisory Group (STAG) meets annually of the Standing Committee, and
to review progress in scientific studies, through periodic independent external
to recommend priorities and to advise evaluations. The last external evaluation,
on the allocation of resources. covering the period 2013–2017, was
presented to PCC in March 2019.****
• The Gender and Rights Advisory
Panel (GAP) reviews the work from the Each of these bodies can assess, from
perspective of gender and rights. different points of view, the achievement of the
programme processes, outputs and outcomes.
**** https://www.who.int/reproductivehealth/about_us/hrp/oversight/en/
10 HRP REVISED PROGRAMME BUDGET, 2020-2021HRP THEMATIC AREAS
A. FAMILY PLANNING AND CONTRACEPTION
Contraception is one of the most effective demand contraception, vaginal rings,
and cost-effective public health interventions. multipurpose prevention technologies),
Its use is increasing worldwide but remains HRP will ensure that there is a clear and
very uneven across regions; it is estimated coordinated pathway to complete the
that some 214 million women living in product development process through pre-
low- and middle-income countries do not qualification and introduction by convening,
want to become pregnant and are not guiding and supporting key stakeholders.
using effective contraceptive methods for
a variety of reasons. Improving access to To meet the increasing demand for services
contraception could decrease maternal in the context of an existing health workforce
mortality by one third worldwide. that is limited in numbers and coverage, and
to reach underserved populations, efforts
Ensuring high standards of quality of care must continue to ensure the provision
across the wide variety of service-delivery of services by the most appropriate and
settings remains a challenge. WHO’s guidelines competent cadre of providers, at different
relating to family planning, which are developed levels of the health system and through
with significant support from HRP, are widely integration with other services. Task sharing
recognized as authoritative. To facilitate of family planning services must be achieved
their use, HRP and the SRH Department will while maintaining a high level of quality
continue to develop consolidated guidelines of care and full respect for human rights.
and derivative tools that are easier to adapt HRP’s contribution will be to synthesize
and use by intended audiences, and that existing evidence from programmatic
improve service availability and delivery. research, coordinate the generation of new
evidence and convene key stakeholders for
This guidance needs to be kept up to date as periodic review and dissemination of the
new scientific evidence becomes available evidence on task sharing and integration.
and potential safety concerns emerge.
HRP will contribute to the global evidence From the perspective of health system
base on safety, efficacy and utilization of strengthening to improve access to modern
contraception through synthesizing existing contraceptives, HRP will coordinate the
evidence, coordinating generation of new evidence base for cost-effective service
evidence and convening key stakeholders. delivery and financing innovations through
multi-site operations research and develop
A wide variety of contraceptive methods guidance for their implementation and
are available. In practice, however, many documentation at scale through coordinating
individuals have a limited choice and there multi-site implementation research.
is a need to continue to develop methods
that are better suited to a wider range of HRP has a key role to play in the process
health needs and living conditions. As new of developing and reporting on SRHR-
or adapted contraceptive technologies related indicators under the Sustainable
become available (e.g. subcutaneous Development Goals (SDGs) and the United
depot medroxyprogesterone acetate Nations’ Global Strategy for Women’s,
[DMPA] self-injection, pericoital or on- Children’s and Adolescents’ Health 2016-
HRP REVISED PROGRAMME BUDGET, 2020-2021 112030. It will take decisive action to ensure that particularly when it comes to the estimation
global agreement is reached on operational of unmet need for contraception called for
definitions and indicators for measuring and under SDG indicator 3.7.1, and to contribute
monitoring contraceptive-use dynamics, to SDG indicators 3.7.2 and 3.8.1.
PRODUCT LISTING
PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
A. FAMILY PLANNING AND CONTRACEPTION
A01 ECHO study close Closing down Dissemination Post ECHO research Priority A
down, country support, of sites and and conference scoping and HRP/CFC
dissemination and archiving of data, session at issues meeting;
research meeting on dissemination; the IAC 2020; dissemination
the post ECHO issues Support country Support country
task teams task teams
A02 Evidence of impact End-line data Closing down of Data analysis and Developing of Priority A
of an intervention collection - cohort, study in country writing of main implementation manual HRP/CFC
promoting community cross section, sites and data manuscripts and dissemination
monitoring and facility audit and analysis
social accountability context mapping
of contraceptive
programmes
A05 Evidence-based Identifying Adapting master Initiating research Analysis and write up Priority A
recommendations countries that protocol to and support HRP/CFC
for implementation want to adapt the local needs
and scale-up of master protocol
subcutaneous DMPA
A06 Leadership of Identification of Alignment of Implementation Progress reports Priority A
Implementing Best priority countries countries with though the IBP WHO core/
Practice (IBP) initiative HIPs and other partners CFC
to implement WHO networks and
guidelines and High- partnerships for
Impact Practice implementation
(HIP) interventions based on needs
through Implementing
Best Practice (IBP)
initiative partners
A10 Policy database Collection of data Data Development Data presentation Priority A
of national sexual on sexual and analysis and of a portal to and use WHO core/
and reproductive reproductive health summarization present the data CFC
health policies and rights policies
and programmes,
including health
systems coverage
A11 Evidence in innovative Identifying focus Adapting master Initiating Data analysis, writing Priority A
financing approaches countries willing protocol to implementation manuscripts and HRP/CFC
(RBF) on effectiveness, to adapt the local context. research with dissemination
efficiency, and equitable master protocol Identification of partners. Monitoring
strategic purchasing implementing and supervision
of contraception and partners
family planning
A12 Strengthening health Synthesis of Synthesis of Report on lessons Report on lessons Priority A
systems response lessons from lessons learned learned on learned on strengthening WHO core/
to accelerate access South-South from scaling strengthening HS response to CFC
to quality and right learning in six up PPFP in six HS response to accelerate access
based contraception countries countries accelerate access to quality and right
and FP services to quality and right based contraception
based contraception and FP services in
and FP services another 8 countries
in 6 countries
12 HRP REVISED PROGRAMME BUDGET, 2020-2021PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
A13 Implementation Identifying focus Adapting master Initiating Data analysis, writing Priority B
research on scaling countries willing protocol to implementation manuscripts and HRP/CFC
up effective family to adapt the local context. research with dissemination
planning counselling master protocol Identification of partners. Monitoring
strategies and implementing and supervision
approaches. partners
A14 Using implementation Identifying focus Adapting master Initiating Data analysis, writing Priority B
research to strengthen countries willing protocol to implementation manuscripts and HRP/CFC
contraceptive to adapt the local context. research with dissemination
programmes supported master protocol Identification of partners. Monitoring
by UNFPA through implementing and supervision
improving access, partners
method mix, and
quality of care
A15 Using implementation Identification of Adapting master Initiating research Data analysis, writing Priority B
research results partners for project protocol to with partners. manuscripts and WHO core/
to improve quality implementation local context Monitoring and dissemination CFC
and range of FP along with Ministry supervision
services in Brazil of Health, Brazil
A16 Knowledge Gateway Call for proposals Development Onboarding Implementation Priority B
online platform of Task Team and Launch of through IBP partners HRP/CFC
strengthened and and Selection New Platform
updated to foster
research collaboration
and partnership
A17 Normative WHO Develop, Develop, update Develop, update, Support the creation of Priority A
guidelines and disseminate and and disseminate and disseminate complementary tools WHO core/
derivative products for implement FP guidelines and guidelines and tools and guidelines, such CFC
family planning services guidelines and tools tools for women for adolescents as those addressing
including the medical such as the Medical living with HIV relevant to family gender-based violence,
eligibility criteria (MEC) Eligibility Criteria and women planning programs training and Task sharing
for contraceptive use and FP Handbook at high risk of and services
HIV relevant to
family planning
programs and
services
A18 Stationery, supplies, Office supplies Postage, Mobile phone and Priority A
postage and and stationary communications communication cost HRP/CFC
communications in for HRP
support of CFC
A19 Stationery, supplies, Office supplies Postage, Mobile phone and Priority A
postage and and stationary communications communication cost WHO core/
communications in for HRP CFC
support of CFC
A20 Preparing for Describing Modelling Generating Landscaping and Priority A
introduction of attitudes of potential of male evidence on impact community sensitization HRP/CFC
reversible non potential male contraception of unintended
coitally dependent and female users as a means to pregnancy on men
male methods engage men in
health care
HRP REVISED PROGRAMME BUDGET, 2020-2021 13B. MATERNAL AND PERINATAL HEALTH
HRP strives to be an agent of transformation Of the 303 000 maternal deaths that occur
for maternal and perinatal health. Its core annually, it is estimated that over 10% are
mission is to perform research and support due to sepsis. Sepsis is also the cause of 15%
the development of WHO guidance and of newborn deaths. HRP will provide global
implementation tools that not only ensure that leadership in preventing and managing maternal
pregnant women and newborn infants survive and neonatal sepsis through coordinating
but which also enable a positive childbirth multi-site research to develop and test clinical
experience and for mothers and infants to innovations, and multi-site implementation
thrive. HRP’s work is guided by strategic research to support adaptation of WHO
priorities for achieving the SDGs, targets 3.1, recommendations on maternal sepsis.
3.2, 3.7 and 3.8, and by the Global Strategy.
HRP has intensified and expanded efforts
Three areas of work related to maternal and across these three broad priority areas
perinatal health have been prioritized by of research and evidence generation with
HRP: antenatal care, intrapartum care and a focus on transitioning from clinical to
maternal sepsis. HRP will develop guidance implementation research for achieving
tools to assist countries in implementing measurable impact at the country level.
WHO recommendations for antenatal care
and intrapartum care at scale, including as New technologies have the potential to
part of WHO’s “Quality, Equity, Dignity” (QED) improve pregnancy and childbirth experience
initiative to improve the quality of maternal and health outcomes. HRP will coordinate
and newborn health care. This guidance will the development of digital and technological
be informed by multi-site implementation innovations, including artificial intelligence
research for health systems strengthening, and, and machine-learning tools, to support
for antenatal care, by developing, testing and decision-making of health care providers.
validating indicators of quality antenatal care.
14 HRP REVISED PROGRAMME BUDGET, 2020-2021HRP has long advocated for rational use of (PPH) to address emerging clinical and
caesarean section, performed exclusively health system organizational challenges.
for medically indicated reasons. It will pursue
this work and provide global leadership in Over the years, HRP has developed a series
optimizing the use of caesarean section of WHO clinical and programmatic guidelines
by conducting multi-site implementation for maternal and perinatal care. It will apply
research for evaluating the effectiveness of innovative approaches to continuously review
interventions, implementation frameworks and these guidelines, undertake revisions as required
processes. Building on the efforts of the last by new evidence, and develop consolidated
biennium, HRP will provide global leadership guidelines and derivative tools that are easier
for research in postpartum haemorrhage to adapt and use by intended audiences.
PRODUCT LISTING
PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
B. MATERNAL AND PERINATAL HEALTH
B02 Interventions for Multi-country Doppler screening Priority A
stillbirth reduction study to assess intervention HRP/MPH
based on Doppler the prevalence strategy for
screening developed of impaired fetal antenatal stillbirth
growth using low reduction identified
cost continuous and plans for
wave doppler research finalized
measurements
completed and
findings published
B03 Guidance for Formative Implementation Country-specific Priority A
implementation preparative research protocols research initiated HRP/MPH
of the 2016 WHO activities for for ANC developed
Antenatal Care Model implementation and approved for
developed through research completed Burkina Faso, India,
implementation in Burkina Faso, Rwanda and Zambia
research India, Rwanda
and Zambia
B05 Effectiveness of a Multi-country Country selection Priority B
novel magnesium randomized control finalized and HRP/MPH
sulfate regimen trial protocol recruitment started
for eclampsia comparing the
prevention and effectiveness
treatment evaluated of alternative
magnesium sulfate
regimens approved
B06 Effectiveness of Opti-BP validation Formative research Priority A
digital and wearable study completed protocol for use of HRP/MPH
technologies in Bangladesh, OptiBP by women
for prediction South Africa and developed
of pregnancy Tanzania, and
complications results published
demonstrated
B07 Quality of care Formative research Research training QUALI-DEC Systematic reviews Priority A
around the time of conducted in workshops strategy for the on assisted vaginal HRP/MPH
childbirth: Optimizing the 4 countries conducted in implementation of birth conducted
caesarean section (Argentina, Burkina selected countries the intervention and published
through quality Faso, Thailand designed and agreed
decision making by and Viet Nam) in the 4 countries
women and providers (Argentina, Burkina
in low- and middle- Faso, Thailand
income countries and Viet Nam)
HRP REVISED PROGRAMME BUDGET, 2020-2021 15PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
B09 Guidance for Strategy for WHO Embedded Priority A
implementing the implementation intrapartum care implementation HRP/MPH
WHO intrapartum of WHO recommendations research projects
care model intrapartum care implemented in developed and
developed through recommendations in selected countries approved for
implementation selected countries implementation in
research developed selected countries
B10 Effective intrapartum New paper-based Intrapartum care SELMA machine Priority A
decision-support tool WHO intrapartum algorithms finalized, learning tool HRP/MPH
developed (SELMA – care guide validated, pilot tested and finalized and
Simplified, Effective, disseminated with validated validated
Labour Monitoring- implementation
to-Action – to support guide
front-line health
workers in labour
management)
B13 Research to assess Reviews and Phase II study Priority A
potential benefits secondary analyses implemented, HRP/MPH
and harms of heat conducted, protocol results analysed,
stable carbetocin for a uterine and manuscript
for postpartum contractility and PK/ submitted for
haemorrhage PD study approved publication
treatment use
implemented
B14 Evidence of the quality Systematic review of WHO participation Essential maternal Priority A
of medicines, devices quality of maternal in Maternal Health health medicines HRP/MPH
and technologies used health medicines Supplies Coalition monitored and PQ
during pregnancy conducted and activities continued requests issued
and childbirth in published as needed
field settings (e.g.
oxytocin, misoprostol)
B15 Evidence of the safety ACTION-I trial in Key secondary ACTION-II research Implementation Priority A
and effectiveness of Bangladesh, India, analyses of priority identified, research protocol HRP/MPH
corticosteroids for Kenya, Nigeria and ACTION-I trial protocol revised, for scale up of
women at risk for Pakistan completed database completed and recruitment ACTION-I trial
preterm birth in low and main findings and published initiated on ACTION findings developed
resource settings published trial platform
B17 Leadership in Recommendations Integrated Priority A
digital platforms and supporting computable WHO Core/
for guidelines on evidence base for guideline package MPH
maternal and perinatal maternal health (including
health developed recommendations algorithms)
presented and developed
disseminated using and finalized
digital platforms for antenatal,
intrapartum and
postnatal care
B18 Living guidelines Quantitative and Biennial Executive Priority A
approach for qualitative evidence Guideline Steering HRP/MPH
dynamic updating syntheses for WHO Group meeting for
of WHO maternal recommendations prioritization of
and perinatal health prioritized for systematic reviews
recommendations update completed for update held
implemented and published
B22 Evidence on Systematic review Mistreatment Palestine Technical support Priority A
interventions for to identify and of women study mistreatment of to WHO Quality, HRP/MPH
respectful care/ assess interventions priority secondary women during Equity, Dignity
experience care for to reduce analyses completed childbirth study Network regarding
improved quality mistreatment and and submitted conducted and experience of
of care generated enable respectful for publication results submitted care components
care during for publication provided
childbirth conducted
16 HRP REVISED PROGRAMME BUDGET, 2020-2021PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
B23 Improving Current Antenatal Toolkit finalized Priority A
antenatal care Care adapted and disseminated WHO core/
MPH
B24 Stationery, supplies, Office supplies Postage, Mobile phone and Priority A
postage and and stationary communications communication cost WHO core/
communications in for HRP MPH
support of MPH
B26 Stationery, supplies, Office supplies Postage, Mobile phone and Priority A
postage and and stationary communications communication cost HRP/MPH
communications in for HRP
support of MPH
B27 Interventions to Secondary analyses Technical Implementation of Priority A
reduce the burden of from GLOSS consultation to prioritised research HRP/MPH
maternal and newborn study completed identify global supported.
sepsis evaluated and submitted priorities for
prevention,
identification and
management of
maternal sepsis
conducted
B28 Locally-tailored Implement and Convene annual Protocol for locally- Priority A
quality of care monitor digital network meetings tailored quality HRP/MPH
improvement maternal and to discuss the improvement
strategies developed perinatal routine challenges and strategies approved,
data collection share the results site selection
system in 50+ finalized, and
hospitals in Nigeria recruitment started
B29 Normative WHO Intrapartum Regional and Strengthening Priority A
guidance and care guidance country technical evidence and action WHO core/
derivative products disseminated support for optimizing the MPH
for Intrapartum Care use of caesarean
section
B30 Interventions to Multi-country Trial protocol Uterine tamponade Priority A
reduce postpartum randomized control on comparative devices Phase II HRP/MPH
haemorrhage trial comparing the efficacy of uterine trial completed
morbidity and effectiveness of tamponade devices
mortality evaluated different uterine approved and
tamponade devices sites identified
recruitment
completed
B31 Interventions to WHO Guideline Recommendations Priority A
enhance transition Recommendations dissemination integrated with HRP/MPH
to motherhood in the for positive conducted including the antenatal care
immediate postnatal transition to infographics and intrapartum
period assessed and motherhood published, regional care guidelines
guidance issued published dissemination
meetings convened
B32 Diet and physical Systematic search i-WIP database Systematic review Priority A
activity based of literature for new updated (Effects of updated with focus HRP/MPH
interventions studies published weight management on data from LMIC
on weight gain interventions
during pregnancy on maternal and
synthesized, fetal outcomes
prioritized in pregnancy:
Individual patient
data (IPD)
meta-analysis of
randomized trials)
B33 Antenatal care Formative phase Country-specific Priority A
digital decision to systematically digital tool HRP/MPH
support systems adapt digital tool implemented,
for policy-maker to country context documented
and care providers conducted and published
HRP REVISED PROGRAMME BUDGET, 2020-2021 17PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
B34 WHO strategic and Annual meetings Priority A
technical leadership of postpartum HRP/MPH
in global priorities haemorrhage
in postpartum research and
haemorrhage research implementation
and normative work priorities held
B35 Postpartum Countries selected, Postpartum Priority B
haemorrhage bundle situation analysis haemorrhage bundle HRP/MPH
implementation completed implementation
research initiated initiated in selected
in two countries facilities
B36 Methodological Development and Network meta- Mixed-methods Priority A
advances in maternal dissemination of analysis (NMA) assessment HRP/MPH
and perinatal methodologies ranking approaches of valuation of
norms standards, to enable use of incorporated into outcomes for
and research different evidence evidence-to- WHO maternal
bases for guideline decision frameworks and perinatal
development for WHO guidelines health guidelines
(i.e., CERQual) conducted
B38 Systematic review of Systematic reviews Strategic expert Priority B
calcium fortification completed and meeting to explore HRP/MPH
and pre-eclampsia published implementation
research on calcium
fortification
conducted
B39 Global roadmap for Roadmap developed Support provided Priority A
improving experience and tested to WHO Regional WHO core/
of care in pregnancy Offices as needed MPH
and childbirth
B40 Reducing Mistreatment Quality of care Priority A
mistreatment and of childbirth during pregnancy WHO core/
improving quality of and childbirth MPH
care during pregnancy
and childbirth
B41 Interventions Expert meetings to GLOSS secondary Toolkit for maternity Priority A
to reduce the review priorities analyses conducted setting developed WHO core/
burden of maternal MPH
sepsis identified
and evaluated
B42 Interventions to Guideline Guideline Priority A
enhance transition development publication and WHO core/
to motherhood in the group meetings dissemination MPH
immediate postnatal
period assessed and
guidance issued
18 HRP REVISED PROGRAMME BUDGET, 2020-2021C. SAFE ABORTION
Globally, an estimated 56.3 million abortions progressive policy development and reform
take place each year. Over the past 25 years, to increase access to safe abortion care
abortion rates declined markedly in high- through documenting the impact of diverse
income regions but have remained static in interpretations and applications of abortion laws
low- and middle-income regions. Less than and policies (both facilitative and restrictive)
half of all abortions take place in circumstances on access to and availability of services.
that would be considered safe, and between
2003–2009, abortion-related deaths Over the past 15 years, HRP has been
accounted for 7.9% of all maternal deaths. recognized for its leadership in the development
An estimated 7 million women seek facility- of WHO’s technical and policy guidance
based care for abortion complications. on safe abortion, which integrates clinical,
health system and human rights issues.
Preventing unsafe abortion has been a strategic Evidence-based updates and revisions to
objective of HRP since its inception, placing it in a the guidelines will continue. Scaling up the
unique position within the UN system to provide use of these guidelines remains a challenge
credible scientific information and guidance to and HRP will develop implementation
countries on understanding and interpreting research to facilitate this process.
abortion data. Measurement of abortion-related
events has always been methodologically A powerful development in recent years has
challenging, but the complexity has increased been the increasing evidence base for moving
manifold with the widespread informal use of medical abortion care to the community level
misoprostol outside of health-care facilities. and for women to self-manage all or parts
HRP will pursue this work and strengthen of the process. Innovative interventions to
the global evidence base of population-level make accurate information, quality-assured
data to measure trends in the magnitude of medications and appropriate back-up care
unsafe abortion and its consequences. available to women in these circumstances
are needed. HRP will develop models of care
HRP will step up its technical support by coordinating multi-site implementation
to countries with a focus on guideline research on task sharing and self-management
implementation and integration of services approaches for increasing the availability
into primary health care and universal health of mifepristone and misoprostol.
coverage. HRP will also continue to guide
PRODUCT LISTING
PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
C. SAFE ABORTION
C01 Evidence of the effectiveness Systematic review Protocol developed Priority A
of decentralized models of of decentralized for implementation HRP/PUA
providing medical abortion models of care research related
of providing to decentralized
medical abortion models of providing
conducted, medical abortion
published
C02 Evidence of effectiveness Pilot study Analysis completed Priority A
of anonymous third party conducted and and submitted HRP/PUA
reporting as a new way to completed for publication
measure abortion safety
C03 Expansion of the Global Database kept Expansion of the Scoping completed Priority A
Abortion Policies Database up-to-date with database platform and plans for 2022- HRP/PUA
quarterly revisions completed 23 comprehensive
update developed
HRP REVISED PROGRAMME BUDGET, 2020-2021 19PRODUCT
PRODUCT
ID MILESTONES CLASSIFICATION
DESCRIPTION
INFORMATION
C04 Evidence on the burden Multi-country Secondary analyses Country level Priority A
of abortion complications survey on abortion led by country evidence-to-policy HRP/PUA
in the facilities complications teams completed, briefs summarizing
in Latin America presented and the country-
completed and submitted for specific data,
primary analysis publication including Global
published Abortion Policies
Database, prepared
C08 Safe abortion technical and Evidence syntheses Recommendations Guideline Survey on values Priority A
policy guidance revised and for the guideline finalized; guideline recommendations and preferences HRP/PUA
updated (clinical; health completed document are disseminated of women for
systems; law and policy; prepared and including briefings safe abortion
human rights; monitoring and submitted for to UN Treaty Bodies care conducted
measurement, task shifting) administrative
clearance
C09 Scale up availability and use Combi-pack Combi-pack Regulatory Engagement with Priority A
of a single package containing procurement distributor(s) approvals for medical abortion HRP/PUA
Mifepristone and Misoprostol, plans developed engaged Combi-pack service provision
both components required for for 5 countries, for pooled/ procurement and community
medical abortion (Combi-pack) based on 2019 single market distribution in place regarding use of
country analyses procurement in five countries Combi-packs in
and in-country five countries
consultations
C12 Evidence based guidance Conduct Priority A
in area of safe abortion travel related WHO
and family planning to fellowship Core/SRT
programme
C13 Generating evidence on Research protocol Implementation Recruitment Priority B
implementation of abortion for assessing the initiated in selected completed, HRP/PUA
laws and policies implementation countries results, analysed
of laws and and submitted
policies related to for publication
comprehensive
abortion care
services developed
and approval
obtained
C14 Supporting policy Strategies Dissemination and In-country partners In-country Priority B
formulation, programme developed and implementation of supported to support for the HRP/PUA
design, implementation implemented for WHO guidelines develop and development of
and monitoring policy, advocacy related to ensure alignment future leaders
and communication comprehensive with country in low- and
initiatives related abortion care plans related to middle-income
to comprehensive comprehensive countries related
abortion care abortion care to comprehensive
abortion care
C15 Multi-country research to Quantitative Systematic Protocol for Priority B
develop and validate tool that review on abortion review of existing primary qualitative HRP/PUA
assesses treatment of women experiences and measurement research in
accessing abortion services stigma completed tools conducted selected countries
and submitted developed,
for publication approvals obtained
C16 Stationery, supplies, postage Office supplies Postage, Mobile phone and Priority A
and communications and stationary communications communication HRP/PUA
in support of PUA for HRP cost
20 HRP REVISED PROGRAMME BUDGET, 2020-2021D. STIS, HIV LINKAGES AND CERVICAL CANCER
The WHO Global health sector strategy on precancerous cervical lesions, and scaling-up
sexually transmitted infections, 2016–2021 HPV vaccination services, in line with the WHO
positions the health sector response to STI draft Global Strategy towards the elimination
epidemics as critical to the achievement of of cervical cancer as a public health problem;
universal health coverage – one of the key and on AMR of gonorrhoea and other STIs.
health targets of the 2030 SDGs. HRP will
provide global leadership by shaping the Building upon the unique process of
research and development pathways for meaningful engagement of communities in the
the development and pre-qualification of development of the 2017 WHO Consolidated
innovations in services for prevention and guideline on sexual and reproductive health
control of STIs, including emerging diseases and rights of women living with HIV4 (13),
such as Zika and Ebola which have recently HRP continues to promote the health and
been found to be sexually transmissible. These well-being, particularly of women living with
innovations include STI vaccines, STI point- HIV, with approaches that are responsive to
of-care tests (POCTs), new treatments for their needs and preferences. This meaningful
gonorrhoea and syphilis, and multipurpose engagement has been done frequently, openly,
prevention technologies (MPTs) to prevent and intentionally to give women living with
both STIs and unintended pregnancy. HRP HIV the opportunity to express their views
will also provide global leadership in the in significant planning and decision-making
development of interventions to prevent STI procedures throughout the development,
within the combination prevention approach dissemination and implementation of the
as well as to address complications of STIs, Guideline. In July 2018, HRP joined nearly 40
including cervical cancer, by synthesizing partners in SRHR and HIV to launch the Call
existing evidence, coordinating generation of to Action to support coordinated actions
new evidence and convening key stakeholders to advance the SRHR and HIV life course
and technical experts to issue consensus needs of all people. HRP involvement is key
statements; this includes congenital syphilis to address the challenges set up by the
within the comprehensive programme of SDGs and these WHO flagship initiatives.
elimination of mother-to-child transmission
of HIV, syphilis and Hepatitis B virus. HRP’s work in HIV-SRHR linkages is cross-
cutting and is reflected in many other activities
Through HRP support, WHO has published across the SRH Department, including on
authoritative guidelines on the prevention family planning, violence against women and
and management (including syndromic girls, STIs, cervical cancer and maternal health.
management) of STIs/reproductive tract It will ensure that HIV–SRHR interventions,
infections (RTIs), and of cervical cancer, SRHR of people living with HIV and vulnerable
as well as on the SRHR of women living to HIV are fully addressed in all guidelines
with HIV. As new evidence emerges, these and service-delivery innovations through
guidelines will be updated, and derivative systematic integration in product design,
tools developed for their adaptation. data analysis and reporting. It will support
research on acceptability, feasibility and costs
Surveillance is a key element of the WHO of integrated service delivery to advance the
Global STI Strategy and STI data are an SRHR of people living with or at risk of HIV,
important component of second-generation including through participatory approaches
HIV surveillance. HRP will support countries to for meaningful community engagement.
improve the quality of their national estimates
and help ensure 2018 baseline data are The SDGs and UHC agendas provide important
established. The SRH Department will support opportunities to reimagine and enhance
and monitor implementation of the Global STI equitable health coverage, which meets the
Strategy, with a special focus on: eliminating needs and rights of all, and of key populations.
mother-to-child transmission (EMTCT) of The Global Health Sector Strategy on STI is
syphilis and HIV; reducing the incidence of aligned with the HIV and Hepatitis strategies
cervical cancer through developing and testing and is built on 5 key strategic directions of
innovations for screening and treatment of which 3 are also included in UHC: (1) availability
HRP REVISED PROGRAMME BUDGET, 2020-2021 21You can also read
